AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
UK trial will see if data trumps hype over ivermectin’s role in COVIDDespite limited data, anti-parasitic drug ivermectin has become widely used in some areas of the world as a Share XUK trial will see if data trumps hype over ivermectin’s role in COVIDhttps://pharmaphorum.com/news/uk-trial-will-see-if-data-trumps-hype-over-ivermectins-role-in-covid/
In a class first, Merck’s Keytruda extends survival in cervical cancerMerck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live Share XIn a class first, Merck’s Keytruda extends survival in cervical cancerhttps://pharmaphorum.com/news/in-a-class-first-mercks-keytruda-extends-survival-in-cervical-cancer/
DTx company Pear shapes public listing with $1.6bn SPAC mergerDigital health company Pear Therapeutics has foregone the traditional initial public offering (IPO) route to a stock exchange Share XDTx company Pear shapes public listing with $1.6bn SPAC mergerhttps://pharmaphorum.com/news/dtx-company-pear-shapes-public-listing-with-1-6bn-spac-merger/
UK gov’t defends NHS data sharing plans in strategy documentThe UK’s Department of Health and Social Care has published a document setting out its strategy on handling Share XUK gov’t defends NHS data sharing plans in strategy documenthttps://pharmaphorum.com/news/uk-govt-defends-nhs-data-sharing-plans-in-strategy-document/
Sanofi and Translate take first mRNA flu vaccine into clinicSanofi and Translate Bio have started a first clinical trial of an mRNA-based seasonal flu vaccine, adding to Share XSanofi and Translate take first mRNA flu vaccine into clinichttps://pharmaphorum.com/news/sanofi-and-translate-take-first-mrna-flu-vaccine-into-clinic/
AZ, MSD’s Koselugo is first EU therapy for neurofibromatosisThe European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share XAZ, MSD’s Koselugo is first EU therapy for neurofibromatosishttps://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
Pair of R&D updates bolster GSK ahead of investor meetingGlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop Share XPair of R&D updates bolster GSK ahead of investor meetinghttps://pharmaphorum.com/news/pair-of-rd-updates-bolster-gsk-ahead-of-investor-meeting/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
